CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
36 hedge funds and large institutions have $104M invested in CERo Therapeutics in 2021 Q4 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
57.16% more ownership
Funds ownership: 0% → 57.16% (+57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$12.2M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$10.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.44M |
| 4 |
SCM
Saba Capital Management
New York
|
+$6.35M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.23M |
Top Sellers
CERO Hedge Fund Activity: Q4 2021 in Review
36 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q4 2021, worth a combined $104M.
Buyers outnumbered sellers: 36 funds opened new CERO positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $12.2M.
- 36 institutional investors held CERo Therapeutics (CERO) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $104M of CERo Therapeutics stock for Q4 2021.
- 36 funds opened new CERo Therapeutics positions in Q4 2021 and 0 closed out, a net change of +36 holders.
- The largest CERo Therapeutics buyer in Q4 2021 was Beryl Capital Management, an estimated $12.2M added.
Based on aggregated 13F filings for Q4 2021.